Combination therapy with transarterial chemoembolization and interferon‐α compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma

Li, Maoquan; Lu, Chenhui; Cheng, Jie; Zhang, Jiaxing; Cao, Chuanwu; Xu, Jiahua; Xu, Jichong; Pan, Hui; Zhong, Bao‐Liang; Tucker, Steven; Wang, Daoyuan

doi:10.1111/j.1440-1746.2009.05863.x

Cited by 27 publications

(25 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the only study that reported median PFS and OS in our systematic review, there is a statistically significant survival benefit for adding antiviral treatment to TACE (p = 0.003) [14]. Alternatively, in the study by Gao et al, the intrahepatic tumour recurrence rate at 1 and 2 years in the TACE + IFN group was 16.1% and 29.0%, compared with 38.7% and 61.3% in the TACE group (p < 0.05).…”

Section: Discussionmentioning

confidence: 68%

“…All patients had intermediate-stage or advanced HCC that was not amenable to liver resection or transplantation. Only four out of the five trials have reported on the severity of liver disease using the Child-Pugh classification system [12][13][14][15]. The majority of patients (58.3-100%) exhibited Child-Pugh class A severity of disease, indicating well-compensated disease.…”

Section: Patient Characteristicsmentioning

confidence: 96%

“…In three out of four studies [12][13][14], the antivirals used were nucleoside analogues (lamivudine 100 mg/day orally, adefovir dipivoxil (10 mg), entecavir (0.5 mg), and telbivudine), whereas in two studies, the antiviral therapy used was interferon alpha (IFN-a1b). In one of these two studies, the dose was three million units (mu) thrice a week by intramuscular injection 1 week after/before TACE treatment, for 48 weeks [15].…”

Section: Treatment Regimensmentioning

confidence: 99%

See 2 more Smart Citations

Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature

Fouad

Abdel‐Rahman

2015

Arab Journal of Gastroenterology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 68%

Section: Patient Characteristicsmentioning

confidence: 96%

Section: Treatment Regimensmentioning

confidence: 99%

See 1 more Smart Citation

Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature

Fouad

Abdel‐Rahman

2015

Arab Journal of Gastroenterology

View full text Add to dashboard Cite

“…Eight studies [30], [34], [37]–[41], [43] aimed to investigate the effect of adjuvant IFN on HCC patients after curative treatment with surgical resection or local ablation therapy. Five [32], [33], [35], [36], [42] studies evaluated the effect of IFN on intermediate and advanced HCC patients. Eleven RCTs studied in Asian populations.…”

Section: Resultsmentioning

confidence: 99%

Effect and Safety of Interferon for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

et al. 2013

View full text Add to dashboard Cite

BackgroundThe effect of interferon(IFN) in the management of hepatocellular carcinoma (HCC) remains controversial, and no clear recommendations have been proposed.ObjectivesTo evaluate the effect and safety of IFN for HCC.MethodsPubMed, OvidSP, and Cochrane Library were searched from their establishment date until August 30, 2012. Studies that met the inclusion criteria were systematically evaluated and then subjected to meta-analysis.ResultsThirteen randomized control trials (RCTs) involving 1344 patients were eligible for this study. When IFN was used as an adjuvant therapy for HCC patients after curative therapy, the meta-analysis showed that IFN reduced the 1-, 2-, 3-, 4-, and 5-year recurrence rates. Subgroup analysis showed that IFN reduced the 2-, 3-, 4-, and 5-year recurrence rates of hepatitis C viral (HCV)-related HCC. The effect of IFN for on hepatitis B virus(HBV)-related HCC patients could not be determined because of isufficient data. After surgical resection, adjuvant IFN therapy reduced the 4- and 5- recurrence rates. All studies reported that IFN could not improve the overall survival of HCV-realated HCC patients after curative therapies. Only one study showed that IFN was associated with better overall survival in HCC patients after curative therapy and subgroup of HCC patients after surgical resection. Thus, meta-analysis was not performed. Different treatment options were used as control to study the effect of IFN for intermediate and advanced HCC patients, thus meta-analysis was not appropriate. All included studies, except for one, reported that IFN treatment was well tolerated.ConclusionsAfter curative therapies, adjuvant IFN reduced the recurrence of HCC. IFN did not improve the survival of HCV-related HCC patients after curative therapy. Whether IFN is effective for intermediate and advanced HCC patients could not be determined because of insufficient data. The toxicity of IFN was acceptable.

show abstract

“…IFN-α-2b also failed to decrease the risk of postoperative recurrence [18] . In contrast, interferon showed some benefits when combined with other modalities such as chemotherapy, curative resection and TACE [19][20][21][22] . Two meta-analyses revealed that adjuvant interferon therapy after curative therapy for HCC could improve both overall survival and recurrence-free survival [23,24] .…”

Section: Cytokinesmentioning

confidence: 99%

Immunotherapy for hepatocellular carcinoma: From basic research to clinical use

Hong

Prasoon

et al. 2015

WJH

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common cancer worldwide with a poor prognosis. Few strategies have been proven efficient in HCC treatment, particularly for those patients not indicated for curative resection or transplantation. Immunotherapy has been developed for decades for cancer control and is attaining more attention as a result of encouraging outcomes of new strategies such as chimeric antigen receptor T cells and immune checkpoint blockade. Right at the front of the new era of immunotherapy, we review the immunotherapy in HCC treatment, from basic research to clinical trials, covering anything from immunomodulators, tumor vaccines and adoptive immunotherapy. The mechanisms, efficacy and safety as well as the approach particulars are unveiled to assist readers to gain a concise but extensive understanding of immunotherapy of HCC.

show abstract

Combination therapy with transarterial chemoembolization and interferon‐α compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma

Abstract: IFN-alpha treatment reduced recurrence and improved the survival of patients after TACE treatment of HBV-related HCC, with acceptable toxicities.

Cited by 27 publications

References 43 publications

Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature

Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature

Effect and Safety of Interferon for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Immunotherapy for hepatocellular carcinoma: From basic research to clinical use

Contact Info

Product

Resources

About